Building specialty psilocybin-based product pipeline Evaluating potential for neuropsychiatric indications for clinical studies in 2022 TORONTO, Nov. 03, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare…


Previous articleU.S. FDA Approves Nova Mentis Orphan Drug Application
Next articleCOMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder